Published in
American Association for the Advancement of Science, Science Immunology, 46(5), 2020
DOI: 10.1126/sciimmunol.aav3942
Links
Tools
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
Journal article published in 2020 by
Margaux Hubert 
,
Elisa Gobbini ,
Coline Couillault ,
Thien-Phong Vu Manh ,
Anne-Claire Doffin ,
Justine Berthet ,
Céline Rodriguez ,
Vincent Ollion ,
Janice Kielbassa,
Christophe Sajous ,
Isabelle Treilleux,
Olivier Tredan ,
Bertrand Dubois ,
Marc Dalod ,
Christophe Caux
and other authors.
,
Elisa Gobbini ,
Coline Couillault ,
Thien-Phong Vu Manh ,
Anne-Claire Doffin ,
Justine Berthet ,
Céline Rodriguez ,
Vincent Ollion ,
Janice Kielbassa,
Christophe Sajous ,
Isabelle Treilleux,
Olivier Tredan ,
Bertrand Dubois ,
Marc Dalod ,
Christophe Caux
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
cDC1-derived IFN-λ is the predominant IFN in breast tumors, and its production can be induced through TLR3-mediated cDC1 activation.